Orthocell has been featured in the widely read column, Dr Boreham’s Crucible. The column, which appeared in Biotech Daily, is written by respected small cap analyst and business journalist, Tim Boreham.
Tim’s commentary follows the recent execution of a global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc for Orthocell’s Striate+™ dental membrane.
Tim Boreham wrote:
“Given the current unsympathetic market conditions, any biotech that tries to raise equity will suffer the equivalent of being stabbed in the eye with a syringe.
Other non-dilutive funding sources are vital, which explains the outbreak of investor joy at Orthocell’s deal in late June to sell the rights to its dental regenerative tool for $23.1 million.”